A Phase I/II, Open-Label, Multicentre Study to Assess The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of AZD4547 in Patients With Relapsed/Refractory Glioma Positive for an FGFR Fusion
Phase of Trial: Phase I/II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs AZD 4547 (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Acronyms TARGET
- 01 Mar 2018 Planned End Date changed from 1 Nov 2017 to 1 Sep 2018.
- 11 Aug 2017 Planned End Date changed from 1 Sep 2016 to 1 Nov 2017.
- 11 Aug 2017 Status changed from recruiting to suspended.